155 related articles for article (PubMed ID: 33542447)
1. Adaptor Template Oligo-Mediated Sequencing (ATOM-Seq) is a new ultra-sensitive UMI-based NGS library preparation technology for use with cfDNA and cfRNA.
Dunwell TL; Dailey SC; Ottestad AL; Yu J; Becker PW; Scaife S; Richman SD; Wood HM; Slaney H; Bottomley D; Yang X; Xiao H; Wahl SGF; Grønberg BH; Dai H; Fu G
Sci Rep; 2021 Feb; 11(1):3138. PubMed ID: 33542447
[TBL] [Abstract][Full Text] [Related]
2. Monitoring of somatic mutations in circulating cell-free DNA by digital PCR and next-generation sequencing during afatinib treatment in patients with lung adenocarcinoma positive for EGFR activating mutations.
Iwama E; Sakai K; Azuma K; Harada T; Harada D; Nosaki K; Hotta K; Ohyanagi F; Kurata T; Fukuhara T; Akamatsu H; Goto K; Shimose T; Kishimoto J; Nakanishi Y; Nishio K; Okamoto I
Ann Oncol; 2017 Jan; 28(1):136-141. PubMed ID: 28177428
[TBL] [Abstract][Full Text] [Related]
3. Next-generation sequencing for tumor mutation quantification using liquid biopsies.
Provencio M; Pérez-Barrios C; Barquin M; Calvo V; Franco F; Sánchez E; Sánchez R; Marsden D; Cristóbal Sánchez J; Martin Acosta P; Laza-Briviesca R; Cruz-Bermúdez A; Romero A
Clin Chem Lab Med; 2020 Jan; 58(2):306-313. PubMed ID: 31469650
[TBL] [Abstract][Full Text] [Related]
4. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
[TBL] [Abstract][Full Text] [Related]
5. Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma.
Rachiglio AM; Esposito Abate R; Sacco A; Pasquale R; Fenizia F; Lambiase M; Morabito A; Montanino A; Rocco G; Romano C; Nappi A; Iaffaioli RV; Tatangelo F; Botti G; Ciardiello F; Maiello MR; De Luca A; Normanno N
Oncotarget; 2016 Oct; 7(41):66595-66605. PubMed ID: 27448974
[TBL] [Abstract][Full Text] [Related]
6. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
[TBL] [Abstract][Full Text] [Related]
7. Profiling of circulating tumor DNA in plasma of non-small cell lung cancer patients, monitoring of epidermal growth factor receptor p.T790M mutated allelic fraction using beads, emulsion, amplification, and magnetics companion assay and evaluation in future application in mimicking circulating tumor cells.
Garcia J; Wozny AS; Geiguer F; Delherme A; Barthelemy D; Merle P; Tissot C; Jones FS; Johnson C; Xing X; Xu Z; Edelstein DL; Brevet M; Souquet PJ; Rodriguez-Lafrasse C; Payen L; Couraud S
Cancer Med; 2019 Jul; 8(8):3685-3697. PubMed ID: 31112372
[TBL] [Abstract][Full Text] [Related]
8. Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.
Hasegawa N; Kohsaka S; Kurokawa K; Shinno Y; Takeda Nakamura I; Ueno T; Kojima S; Kawazu M; Suehara Y; Ishijima M; Goto Y; Kojima Y; Yonemori K; Hayashi T; Saito T; Shukuya T; Takahashi F; Takahashi K; Mano H
Cancer Sci; 2021 Oct; 112(10):4393-4403. PubMed ID: 34310819
[TBL] [Abstract][Full Text] [Related]
9. Variants with a low allele frequency detected in genomic DNA affect the accuracy of mutation detection in cell-free DNA by next-generation sequencing.
Wang JF; Pu X; Zhang X; Chen K; Xi Y; Wang J; Mao X; Zhang J; Heymach JV; Antonoff MB; Hofstetter WL; Mehran RJ; Rice DC; Roth JA; Sepesi B; Swisher SG; Vaporciyan AA; Walsh GL; Meng QH; Shaw KR; Eterovic AK; Fang B
Cancer; 2018 Mar; 124(5):1061-1069. PubMed ID: 29178133
[TBL] [Abstract][Full Text] [Related]
10. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.
Papadopoulou E; Tsoulos N; Tsantikidi K; Metaxa-Mariatou V; Stamou PE; Kladi-Skandali A; Kapeni E; Tsaousis G; Pentheroudakis G; Petrakis D; Lampropoulou DI; Aravantinos G; Varthalitis I; Kesisis G; Boukovinas I; Papakotoulas P; Katirtzoglou N; Athanasiadis E; Stavridi F; Christodoulou C; Koumarianou A; Eralp Y; Nasioulas G
PLoS One; 2019; 14(12):e0226853. PubMed ID: 31860648
[TBL] [Abstract][Full Text] [Related]
11. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
[TBL] [Abstract][Full Text] [Related]
12. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity, specificity, and accuracy of a liquid biopsy approach utilizing molecular amplification pools.
Garcia J; Kamps-Hughes N; Geiguer F; Couraud S; Sarver B; Payen L; Ionescu-Zanetti C
Sci Rep; 2021 May; 11(1):10761. PubMed ID: 34031447
[TBL] [Abstract][Full Text] [Related]
14. Validation of a next-generation sequencing assay for the detection of EGFR mutations in cell-free circulating tumor DNA.
Stitz R; Buder A; Silye R; Baumgartner B; Pühringer F; Filipits M; Oberndorfer E; Heitzer E
Exp Mol Pathol; 2021 Dec; 123():104685. PubMed ID: 34560086
[TBL] [Abstract][Full Text] [Related]
15. A Prospective Study of Circulating Tumor DNA to Guide Matched Targeted Therapy in Lung Cancers.
Sabari JK; Offin M; Stephens D; Ni A; Lee A; Pavlakis N; Clarke S; Diakos CI; Datta S; Tandon N; Martinez A; Myers ML; Makhnin A; Leger Y; Yu HA; Paik PK; Chaft JE; Kris MG; Jeon JO; Borsu LA; Ladanyi M; Arcila ME; Hernandez J; Henderson S; Shaffer T; Garg K; DiPasquo D; Raymond CK; Lim LP; Li M; Hellmann MD; Drilon A; Riely GJ; Rusch VW; Jones DR; Rimner A; Rudin CM; Isbell JM; Li BT
J Natl Cancer Inst; 2019 Jun; 111(6):575-583. PubMed ID: 30496436
[TBL] [Abstract][Full Text] [Related]
16. Liquid Biopsy for Disease Monitoring in Non-Small Cell Lung Cancer: The Link between Biology and the Clinic.
Fernandes MGO; Sousa C; Pereira Reis J; Cruz-Martins N; Souto Moura C; Guimarães S; Justino A; Pina MJ; Magalhães A; Queiroga H; Marques JA; Machado JC; Costa JL; Hespanhol V
Cells; 2021 Jul; 10(8):. PubMed ID: 34440680
[TBL] [Abstract][Full Text] [Related]
17. SiNVICT: ultra-sensitive detection of single nucleotide variants and indels in circulating tumour DNA.
Kockan C; Hach F; Sarrafi I; Bell RH; McConeghy B; Beja K; Haegert A; Wyatt AW; Volik SV; Chi KN; Collins CC; Sahinalp SC
Bioinformatics; 2017 Jan; 33(1):26-34. PubMed ID: 27531099
[TBL] [Abstract][Full Text] [Related]
18. Duplex Proximity Sequencing (Pro-Seq): A method to improve DNA sequencing accuracy without the cost of molecular barcoding redundancy.
Pel J; Choi WWY; Leung A; Shibahara G; Gelinas L; Despotovic M; Ung WL; Marziali A
PLoS One; 2018; 13(10):e0204265. PubMed ID: 30278055
[TBL] [Abstract][Full Text] [Related]
19. Targeted deep sequencing of cell-free DNA in serous body cavity fluids with malignant, suspicious, and benign cytology.
Yang SR; Mooney KL; Libiran P; Jones CD; Joshi R; Lau HD; Stehr H; Berry GJ; Zehnder JL; Long SR; Kong CS; Kunder CA
Cancer Cytopathol; 2020 Jan; 128(1):43-56. PubMed ID: 31751001
[TBL] [Abstract][Full Text] [Related]
20. Construction of a reference material panel for detecting
Xu J; Qu S; Sun N; Zhang W; Zhang J; Song Q; Lin M; Gao W; Zheng Q; Han M; Na C; Xu R; Chang X; Yang X; Huang J
J Clin Pathol; 2021 May; 74(5):314-320. PubMed ID: 32817175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
